There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Thirty-two rhesus monkeys were used to evaluate the dose response of a recombinant
HEV vaccine, and the efficacy of the vaccine based on the ORF2 protein of the Pakistani
strain for pre- and post-exposure vaccination against intravenous challenge with homologous
or heterologous virus was examined. Post-exposure vaccination did not protect animals
against hepatitis. Although primates vaccinated twice with 50-microgram, 10-microgram,
2-microgram, or 0.4-microgram doses of the recombinant 55 kDa ORF-2 protein were infected,
they were protected from hepatitis when they were challenged with very high doses
of the homologous strain of HEV. Primates vaccinated twice with a 50 micrograms dose
of the recombinant protein were protected from hepatitis after heterologous challenge
with the Mexican strain, the strain of HEV most genetically distant from the Pakistani
strain.